Image For Activity Cover
CAR T-Cell Therapies: Special Considerations for Federal and Public Health Settings

Intended Audience: Hematology/oncology teams, including physicians, NPs/PAs, pharmacists, nurses, and case managers, in the federal and public health settings

As CAR T-Cell approaches revolutionize treatment for hematologic malignancies, unique challenges arise in federal and public health settings. Join this live session to hear the latest evidence and expert insights on practical considerations for integrating CAR T-Cell Therapies into treatment for patients with hematologic malignancies.

This webinar is delivered in partnership with AMSUS, The Society of Federal Health Professionals.

Learning Objectives
  • Discuss current evidence and guidelines for the diagnosis, treatment, and management of hematologic malignancies
  • Assess new safety and efficacy data guiding the optimal use of targeted agents and immunotherapies in appropriate patients
  • Implement evidence-based strategies for reducing disparities in care access and treatment in the federal and public health settings

I. Identifying potential candidates for CAR T-cell therapy across hematologic malignancies

II. Addressing barriers to access and supporting successful outcomes with CAR T-cell therapy

III. Case-based discussions in CAR T-cell treatment


Larry D Anderson, Jr, MD, PhD

Larry D Anderson, Jr, MD, PhD

Director of the Myeloma, Waldenström's, and Amyloidosis Program
Associate Professor of Internal Medicine
Division of Hematology/Oncology
UT Southwestern Medical Center
Dallas, TX

Caron A Jacobson, MD

Caron A Jacobson, MD

Medical Director, Immune Effector Cell Therapy Program
Dana Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Ryan J Atkinson, PharmD, MBA

Ryan J Atkinson, PharmD, MBA

Senior Director of Specialty Pharmacy Strategy
Maxor National Pharmacy Services, LLC
Indianapolis, IN

João L Ascensão, MD, PhD, FACP

Course Director
João L Ascensão, MD, PhD, FACP

Professor, Department of Medicine
George Washington University School of Medicine
Clinical Professor of Medicine, Uniformed Services University
Adjunct Professor of Medicine, Georgetown University Medical School
Chief, Hematology and Medical Oncology
Chair, Institute for Clinical Research (ICR)
Washington DC VA Medical Center
Washington, DC

Joyce M Knestrick, PhD, CRNP, FAANP


Visiting Professor
George Washington University
Family Nurse Practitioner
Wheeling Health Right
Wheeling, WV

Mark A Rubin, MD


Medical Director
Fort Lauderdale, FL

Michele B Kaufman, PharmD, BCGP

Peer Reviewer

New York Presbyterian Hospital - Lower Manhattan
New York, NY

CE Details & Instructions

Joint Accreditation Statement

IPCE Credit™
In support of improving patient care, PRIME® is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Teams

Joint AccreditationThis activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physician Credit Designation Statement


PRIME® designates this Live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

MOC Points

ACCME MOC LogoSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Physician Assistant Accreditation Statement


PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioner Accreditation Statement

Nurse Practitioner LogoPRIME Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 060815. This activity is approved for 1.0 contact hour (which includes 0 hour of pharmacology).

Pharmacist Accreditation Statement


This Application-based activity has been approved for 1.0 contact hour (0.1 CEUs) by PRIME® for pharmacists. The Universal Activity Number for this activity is JA0007144-0000-21-192-L01-P . Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity by providing your NABP ID & DOB, which must be submitted within 60 days of completion. Pharmacists with questions can contact NABP customer service ([email protected]).

Nurse Accreditation Statement


PRIME® designates this activity for 1.0 contact hour.

Case Manager Accreditation Statement

CCM Logo

The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers. Credits for this program are pre-approved.

Obtaining CE Credit
  1. Register using the online form
  2. Complete the pre-registration survey
  3. Attend the live program in its entirety
  4. Complete an online evaluation and post-test
  5. Download and/or print a certificate of completion and/or submit CE credits electronically

Instructions to access CME/CE credit options will be provided at the end of the program.

Method of Participation
This live CME/CE activity requires attendance of the participant during the entire program and completion of learner assessment tools. The learner will then receive instructions on how to download and/or print a certificate of completion and/or submit CE credits electronically.
Device Requirements
  • Hardware: an Internet-enabled computer, smartphone, tablet, or mobile device with audio capabilities and Internet connectivity
  • Software: the installation of software such as GoToWebinar may be required
Faculty Disclosures

*PRIME® has identified, reviewed, and mitigated all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to the delivery of any educational activity.

The following individuals have identified relevant financial relationships with commercial interests to disclose:

  • Larry D Anderson, Jr, MD, PhD (Speaker)
    Advisory Board or Panel – AmgenBristol Myers Squibb/CelgeneCelgeneGlaxoSmithKlineJanssenKaryopharmOncopeptides
    Consultant – AmgenBristol Myers Squibb/CelgeneCelgeneGlaxoSmithKlineJanssenKaryopharmOncopeptides
  • Caron A Jacobson, MD (Speaker)
    Advisory Board or Panel – AbbVieBMS/CelgeneKite/Gilead SciencesLonzaNkartaNovartisPrecision Biosciences
    Consultant – AbbVieBMS/CelgeneKite/Gilead SciencesLonzaNkartaNovartisPrecision Biosciences
    Grants / Research Support – Kite/Gilead SciencesPfizer
    Speakers Bureau or other Promotional Education – BMS/Celgene
  • João L Ascensão, MD, PhD, FACP (Course Director, Speaker)
    Advisory Board or Panel – Incyte
  • Manali I Patel, MD, MPH, MS (Speaker)
    Consultant – CelgeneThymeCare
  • Paul M Barr, MD (Speaker)
    Consultant – AbbVieAstraZenecaCelgeneGenentechJanssenMerckPharmacyclicsSeattle GeneticsTG therapeuticsVerastem
    Grants / Research Support – AstraZenecaTG therapeutics
  • Susan M O'Brien, MD (Speaker)
    Consultant – AbbieAlexionAmgenAptose BiosciencesAstellasAutolusBristol-Myers SquibbCelgeneDynaMedEli Lilly and CompanyGlaxoSmithKlineJanssen OncologyJohnson & JohnsonJuno TherapeuticsMEI Pharma Inc.MerckNOVA Research CompanyPfizzerPharmacyclicsRegeneronSunesisTG TherapeuticsVaniam Group LLCVerastemVida Ventures
    Grants / Research Support – AcertaAutolusCaribouGilead SciencesKitePfizzerPharmacyclicsSunesisTG Therapeutics
  • Peter Martin, MD (Speaker)
    Advisory Board or Panel – BeigeneTakeda
    Consultant – ADCTAstraZenecaBayerBeigeneBristol-Myers SquibbCellectarEpizymeGilead SciencesIncyteJanssenKaryopharmMerckMorphosysRegeneronTeneobioVerastem
    Grants / Research Support – Karyopharm
  • Joshua F Zeidner, MD (Speaker)
    Advisory Board or Panel – AstexBristol-Myers SquibbGenentechServierShattuck Labs
    Consultant – AbbVieAstex
    Grants / Research Support – ArogAstexGenentechServierTolero
  • Daniel A Pollyea, MD, MS (Speaker)
    Advisory Board or Panel – AbbVieAmgenApreaAstellasBristol-Myers SquibbCelgeneFoghornGenentechGilead SciencesJazzKaryopharmKiadisNovartisSyndaxSyrosTakeda
    Consultant – AbbVieAmgenApreaAstellasBristol-Myers SquibbCelgeneFoghornGenentechGilead SciencesGlycomimeticsKaryopharmKiadisNovartisSyndaxSyrosTakeda
    Grants / Research Support – AbbVieKaryopharmTeva Pharmaceuticals
  • Joseph R Mikhael, MD, MEd, FRCPC, FACP (Speaker)
    Consultant – AmgenCelgeneGlaxoSmithKlineJanssenKaryopharm TherapeuticsOncopeptidesSanofiTakeda
  • Rafael Fonseca, MD (Speaker)
    Advisory Board or Panel – Adaptive BiotechnologiesOncoTracker
    Consultant – AbbVieAduroAmgenBayerBristol-Myers SquibbCelgeneGlaxoSmithKlineJanssenJunoKiteMerckNovartisOncoTrackerPharmacyclicsSanofiTakeda
  • William Wachsman, MD, PhD (Moderator)
    Consultant – Curio Inc.
    Stock / Shareholder (self- managed) – Prudential Inc.

The following individuals have no relevant financial relationships with commercial interests to disclose:

  • Ryan J Atkinson, PharmD, MBA (Moderator)
  • Michele B Kaufman, PharmD, BCGP (Reviewer)
  • Joyce M Knestrick, PhD, CRNP, FAANP (Planner)
  • Mark A Rubin, MD (Planner)

All PRIME® staff participating in planning and content development have no relevant financial relationships with commercial interests to disclose.

Funding Disclosure
This activity is provided by PRIME Education. There is no fee to participate. This activity is supported by educational grants from AbbVie, Inc., Astellas, Bristol-Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Taiho Oncology, Inc.
Accessibility Statement
At PRIME, we are committed to ensuring that individuals with disabilities can access all of the content offered by PRIME through our website and other properties. If you are having trouble accessing, please email [email protected] for assistance. Please put "ADA Inquiry" in the subject line of your email.
Availability: On-Demand
Access expires on 02/15/2022
Cost: FREE
Credit Offered:
1 AMA PRA Category 1 Credit™ Credit
1 ANCC Credit
1 AANP Credit
1 AAPA Credit
1 ACPE Credit
             Submit a Support Ticket
             Write Us a Friendly Review